FTO-mediated m⁶ A modification of SOCS1 mRNA promotes the progression of diabetic kidney disease

Clin Transl Med. 2022 Jun;12(6):e942. doi: 10.1002/ctm2.942.

Authors

Qiang Sun¹, Houfa Geng², Meng Zhao¹, Yang Li³, Xi Chen¹, Qian Sha¹, Peng Lai², Daoquan Tang¹, Dongzhi Yang¹, Jun Liang^{1

2}, Mengzhe Guo¹

Affiliations

¹ Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu, China.
² Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Clinical School of Nanjing Medical University, Xuzhou, Jiangsu, China.
³ Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

No abstract available

Keywords: diabetic kidney disease; m6A modification; single-cell omics.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenosine
Alpha-Ketoglutarate-Dependent Dioxygenase FTO / genetics
Alpha-Ketoglutarate-Dependent Dioxygenase FTO / metabolism
Diabetes Mellitus*
Diabetic Nephropathies* / genetics
Humans
RNA, Messenger / genetics
Suppressor of Cytokine Signaling 1 Protein
Suppressor of Cytokine Signaling Proteins

Substances

RNA, Messenger
SOCS1 protein, human
Suppressor of Cytokine Signaling 1 Protein
Suppressor of Cytokine Signaling Proteins
Alpha-Ketoglutarate-Dependent Dioxygenase FTO
FTO protein, human
Adenosine